Halia Therapeutics is a clinical-stage biopharmaceutical company headquartered in Lehi, Utah, focused on novel small-molecule therapies targeting chronic inflammation and neuroinflammation. Its lead candidate, HT-6184, is a selective, orally bioavailable first-in-class inhibitor of the NLRP3/NEK7 inflammasome and has completed a Phase 1 study. HT-6184 is advancing in global Phase II development, with a Phase IIa trial initiated in India for lower-risk myelodysplastic syndromes and planned Phase II studies in the U.S. for post-procedure inflammatory pain, plus a planned Phase I trial in Alzheimer's patients. The company is also developing LRRK2 inhibitor programs for neurological diseases such as Parkinson's and Alzheimer's and is preparing IND-enabling studies. Proceeds from recent financing will support ongoing clinical trials, IND-enabling work for alternative programs, and expansion of clinical and regulatory teams to support global development.

Total raised

$30M

Funding rounds

1

Latest round

Series C

Latest activity

Jan 2024